Moderna's narrative is shifting as analysts modestly trim their fair value from $37.32 to $35.78 per share and nudge the ...

The Dow Jones index fell on the stock market today. Synopsys popped on an investment from AI giant Nvidia. A gold stock cleared an entry.

Valued at $10.2 billion by market cap, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) operates as a clinical-stage ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $22.0 to $39.0 for Moderna over the last 3 months.

Moderna (MRNA) slipped about 6% after an FDA official said future vaccine approvals will face tougher scrutiny, a shift tied ...

Moderna MRNA is set to report third-quarter 2025 earnings on Nov. 6, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $860 million and a loss of $2.15 per ...

Moderna shares fell over 4% after the FDA signaled stricter vaccine approval rules, raising concerns about potential delays for new vaccines.

Moderna’s third-quarter results weren’t as bad as they could have been, which was enough to trigger a rally in the stock on Thursday.

Moderna Inc. fell in trading Monday after the Food and Drug Administration said in a memo late last week it would place new restrictions on which vaccines hit the market. Vinay Prasad, a top FDA ...

What To Know: A memo obtained by NBC News said Prasad told FDA staff that an internal review found at least 10 child deaths "after and because of receiving" the Covid vaccine, citing reports in the ...